

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Debyser et al

Serial No. 09/403,625

Filed: February 7, 2000

For: INHIBITORS OF CELLULLOLYTIC, XYLANOLYTIC AND  
BETA-GLUCANOLYTIC ENZYMES



Atty. Ref.: 550-392

Group: 1652

Examiner: Fronda

#19  
M.G.J  
7/17/03

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

June 26, 2003

Sir:

**INFORMATION DISCLOSURE STATEMENT**

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits] **N/C**

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e))  
Statement or Rule 17(p) fee] **N/C**

2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e))  
Statement or Rule 17(p) fee] **\$180.00**

3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e))  
Statement and Rule 17(p) fee), but before final fee payment] **\$180.00**

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of

06/27/2003 WARDER1 000000016 141140 09403625  
01 FC:1806 180.00 DA

749955

each non-English language document (such as a Search Report) is enclosed herewith.

The Examiner is urged to review copending application Serial No. 10/311,886, the text of which is attached as WO 01/98474.


Also listed on the attached PTO-1449 Forms are U.S. Patents submitted as Exhibits A-C with the Amendment dated May 6, 2002.

This paper is submitted in accordance with:

- 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
  - a) The required Statement made in item 8 below; or
  - b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
  - a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
  - b) The required Statement is stated in item 8 below.
- 8. Statement under 37 CFR 1.97(e)
  - a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
  - b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: 

B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Bailey, et al., "Production of xylanases by <i>Aspergillus fumigatus</i> and <i>Aspergillus oryzae</i> on xylan-based media", <i>World Journal of Microbiology and Biotechnology</i> , Vol. 9, 1993.
	McLauchlan, et al., "A novel class of protein from wheat which inhibits xylanases", <i>Biochem. J.</i> (1999) 338, 441-446.
	Debyser, et al., "Triticum aestivum Xylanase Inhibitor (TAXI), a New Class of Enzyme Inhibitor Affecting Breadmaking Performance", <i>Journal of Cereal Science</i> 30 (1999) 39-43.
	Gebruers, et al., "Triticum aestivum L. endoxylanase inhibitor (TAXI) consists of two inhibitors, TAXI I and TAXI II, with different specificities", <i>Biochem. J.</i> (2001) 353, 239-244.
	Goesaert, et al., "Purification and Partial Characterization of an Endoxylanase Inhibitor from Barley", <i>American Association of Cereal Chemists, Inc.</i> , Vol. 78, No. 4, 2001.

#### EXERCISES

**Date Considered**

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**Form PTO-FB-A820 (Also PTO-1449)**